Phenotypes

Targeted Treatments for a Devastating Disease: What Subphenotypes of ARDS May Mean for Your ICU

Concurrent Session Moderator(s)

• 

  Craig Jabaley, MD, FCCM

  Associate Professor of Anesthesiology
  Emory University Hospital
  Atlanta, Georgia

  Disclosure(s): No relevant financial relationship(s) to disclose.
• 

  Katherine McCusker (she/her/hers)

  ARNP
  University of Washington

  Disclosure information not submitted.

Acute respiratory distress syndrome (ARDS), a severe lung disorder with devastating inflammation, is associated with high morbidity and mortality. Despite active research attempting to develop pharmacologic agents for ARDS, treatment remains supportive only. Recently, the analysis of large ARDS cohorts from randomized controlled trials have yielded the identification of specific subphenotypes. This session will review the physiologic and biologic ARDS subphenotypes and examine current research on the inflammatory markers associated with specific origins of ARDS. The significant difference in outcomes among subphenotypes with different ventilator strategies will be highlighted. Future directions in pulmonary biology and potential targeted therapies within each subphenotype will be discussed.

Presentations:

• Physiologic Subphenotypes in ARDS: Can They Make a Difference?
  

  Concurrent Session Faculty: Carolyn S. Calfee, MD, MS – University of California San Francisco Medical Center
• Don't Be So Inflammatory: Understanding Biologic Inflammatory Subphenotypes in ARDS
  

  Concurrent Session Faculty: Jennifer G. Wilson, MD, MS – Stanford University School of Medicine
• Mixing It Together: Recipe for Translational and Genomic Target Therapy Subphenotypes in ARDS
  

  Concurrent Session Faculty: Craig S. Jabaley, MD, FCCM – Emory University Hospital